Generic Cosopt approved

Article

Hi-Tech Pharmacal Co., Inc. has announced that the FDA has granted tentative approval to the company's Abbreviated New Drug Application (ANDA) for dorzolamide hydrochloride with timolol maleate ophthalmic solution, the generic equivalent of Merck's Cosopt.

Hi-Tech Pharmacal Co., Inc. has announced that the FDA has granted tentative approval to the company's Abbreviated New Drug Application (ANDA) for dorzolamide hydrochloride with timolol maleate ophthalmic solution, the generic equivalent of Merck's Cosopt.

Hi-Tech will begin marketing the product upon the completion of Merck's paediatric exclusivity period in October 2008. According to IMS, Merck's Cosopt had sales of $334 million in 2007.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Related Content
A blue hazard sign, an exclamation point (!) inside a triangle, to communicate the risks of misdiagnosing geographic atrophy and age-related macular degeneration. Image credit: ©jcsnb – stock.adobe.com

Researchers raise awareness of macular pathologies which mimic AMD and GA

Lynda Charters
March 20th 2025
Article

Inherited retinal diseases have disease processes distinct from age-related macular degeneration and geographic atrophy, but may present with "phenocopy" clinical signs

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
A woman stands at a mirror, inserting a contact lens. Image credit: ©Camerene Pendl/peopleimages.com – stock.adobe.com

Bausch + Lomb launches Arise orthokeratology lens fitting system in Europe, UK and US

Jordana Joy
March 17th 2025
Article

The Arise system utilises advanced algorithms to interpret corneal topography images, recommending lenses without requiring a fitting set

Images of a chest X-ray and a CT scan show the chest and vascular system following a COVID-19 infection. Image credit: ©samunella – stock.adobe.com

EDI-OCT and CVI findings can shed light on choroidal vascular physiology following COVID-19 pneumonia

Lynda Charters
March 17th 2025
Article

Investigators measured the choroidal structures using enhanced depth imaging optical coherence tomography

An image of the old town in Winterthur, Switzerland, showing buildings and clock towers. Image credit: ©bill_17 – stock.adobe.com

Winterthur, Switzerland welcomes second annual Winterthur Ophthalmology Symposium

Hattie Hayes
March 14th 2025
Article

After a successful inaugural WOS in 2024, the congress will feature new lectures and wetlabs in its sophomore year

An eye doctor administers cyclosporine eye drops to a patient. Image credit: ©smile35 – stock.adobe.com

Study assesses efficacy of cyclosporine A 0.1% cationic emulsion drops for postoperative discomfort

Lynda Charters
March 14th 2025
Article

Prophylactic cyclosporine A 0.1% eye drops were associated with improved ocular surface homeostasis and reduced inflammation

© 2025 MJH Life Sciences

All rights reserved.